知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.026 秒)

    HIV-specific T-cell induction
    4.
    发明授权
    HIV-specific T-cell induction 失效
    HIV特异性T细胞诱导

    公开(公告)号：US06656471B1

    公开(公告)日：2003-12-02

    申请号：US09440772

    申请日：1999-11-16

    申请人： K. Jagannadha Sastry ,  Ralph B. Arlinghaus ,  Pramod N. Nehete

    发明人： K. Jagannadha Sastry ,  Ralph B. Arlinghaus ,  Pramod N. Nehete

    IPC分类号： A61K3800

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2740/16122 ,  G01N33/5091 ,  G01N33/56977 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  Y10S530/826

    摘要： This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.

    摘要翻译： 本发明公开了AIDS的诊断，预防和治疗方法，涉及确定受试者是否表现HLA-Cw7限制性CTL应答。 一些方法涉及使用HLA-Cw7作为长期非进展和治疗疗法适应性的遗传标记。 诊断方法包括预测HIV感染受试者长期不进展的方法。 预防和治疗方法包括确定受试者是否表现出HLA-Cw7限制性CTL应答。 如果有必要，它们还包括引发此类响应的方法。 此外，一些方法包括施用一种或多种HIV多肽或肽或编码它们的多核苷酸作为预防AIDS发展的治疗疗法。

    BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
    5.
    发明授权
    BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth 失效
    BCR-ABL定向组合物和用于抑制Philadelphia chromesome刺激的细胞生长的用途

    公开(公告)号：US06537804B1

    公开(公告)日：2003-03-25

    申请号：US09101059

    申请日：1999-06-21

    申请人： Ralph B. Arlinghaus ,  Jiaxin Liu ,  Gabriel Lopez-Berestein ,  Dai Lu ,  Yun Wu

    发明人： Ralph B. Arlinghaus ,  Jiaxin Liu ,  Gabriel Lopez-Berestein ,  Dai Lu ,  Yun Wu

    IPC分类号： C07H2104

    CPC分类号： C07K14/82 ,  A61K38/00

    摘要： The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.

    摘要翻译： 本发明提供了用于检测和定量Bcl-ABL基因产物和Ph1阳性白血病细胞的其他异常ABL基因产物的方法。 本发明还提供了用于确定与正常ABL细胞相比的白血病细胞的相对数量以评估患者的肿瘤负担的方法。 另一方面，本发明的方法可用于测定白血病特异性阶段，特别是慢性期CML。

    Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
    6.
    发明授权
    Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth 失效
    Bcr-Abl定向组合物和用于抑制费城染色体刺激的细胞生长的用途

    公开(公告)号：US6107457A

    公开(公告)日：2000-08-22

    申请号：US390353

    申请日：1995-02-16

    申请人： Ralph B. Arlinghaus ,  Jiaxin Liu ,  Dai Lu ,  Gabriel Lopez-Berestein

    发明人： Ralph B. Arlinghaus ,  Jiaxin Liu ,  Dai Lu ,  Gabriel Lopez-Berestein

    IPC分类号： C12N15/09 ,  A61K35/76 ,  A61K38/00 ,  A61P31/12 ,  C07K14/82 ,  C12N5/08 ,  C12N15/12 ,  C12P21/02 ,  C07K7/00 ,  C07K14/00

    CPC分类号： C07K14/82 ,  A61K38/00

    摘要： Compositions comprising a mixture of peptides that bind to molecules involved in Bcr-Abl oncoprotein function are disclosed. In addition, expression of functional BCR protein (p160 BCR) or amino terminal fragments thereof (159, 221 and 413 amino terminal residues) by way of retrovirus vectors will oppose the biological function of Bcr-Abl (p160 BCR) or inactivate Bcr-Abl tyrosine kinase function or its signal transduction function. Bcr and Abl peptides, either tyrosine phosphorylated or unphosphorylated, that bind to a region near the amino terminus of Bcr to prevent formation of tetramer Bcr-Abl molecules, that bind to the SH2 domain of Grb2, to sites on tyrosine phosphorylated Shc protein, to sites of Crkl, and to an SH2 domain of Ras Gap comprise particular peptide preparations of the invention. The peptides and polypeptides inhibit Bcr-Abl oncoprotein activation, or block the oncogenic signal generated by the Bcr-Abl oncoprotein and, thereby, inhibit growth and induce cell death of leukemia cells expressing the oncoprotein. Methods for processing bone marrow using the peptide and polypeptide compositions of the invention are also provided. Stem cells present in bone marrow may thus be enriched for Philadelphia chromosome-negative cells prior to transplantation, particularly as part of autologous bone marrow transplant therapy of leukemia, including CML, ALL and AML.

    摘要翻译： 公开了包含与参与Bcr-Abl癌蛋白功能的分子结合的肽的混合物的组合物。 此外，通过逆转录病毒载体的功能性BCR蛋白（p160BCR）或其氨基末端片段（159,221和413氨基末端残基）的表达将反对Bcr-Abl（p160BCR）的生物学功能或者使Bcr-Abl失活 酪氨酸激酶功能或其信号转导功能。 Bcr和Abl肽，酪氨酸磷酸化或未磷酸化，其结合到Bcr的氨基末端附近的区域，以防止结合到Grb2的SH2结构域的四聚体Bcr-Abl分子到酪氨酸磷酸化的Shc蛋白上的位点到 Crk1的位点和Ras Gap的SH2结构域包含本发明的特定的肽制剂。 肽和多肽抑制Bcr-Abl癌蛋白激活，或阻断由Bcr-Abl癌蛋白产生的致癌信号，从而抑制表达癌蛋白的白血病细胞的生长并诱导细胞死亡。 还提供了使用本发明的肽和多肽组合物处理骨髓的方法。 因此，存在于骨髓中的干细胞可以在移植之前被富集成为费城染色体阴性细胞，特别是作为白血病（包括CML，ALL和AML）的自体骨髓移植治疗的一部分。

    Prophylaxis and therapy of acquired immunodeficiency syndrome
    7.
    发明授权
    Prophylaxis and therapy of acquired immunodeficiency syndrome 失效
    获得性免疫缺陷综合征的预防和治疗

    公开(公告)号：US5128319A

    公开(公告)日：1992-07-07

    申请号：US410727

    申请日：1989-09-20

    申请人： Ralph B. Arlinghaus

    发明人： Ralph B. Arlinghaus

    IPC分类号： A61K39/00 ,  A61K39/21 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/16 ,  G01N33/50

    CPC分类号： C07K14/005 ,  G01N33/505 ,  A61K39/00 ,  C12N2740/16122 ,  G01N2333/16

    摘要： An active peptide consisting essentially of 7 to about 30 residence and having a sequence that corresponds to a conserved domain of an HIV protein is disclosed, as is a multimer containing that peptide, an aqueous composition containing the multimer and methods of using and making the same. The aqueous composition containing an immunologically effective amount of an active peptide multimer, when introduced into an immunocompetent host animal in an immunologically effective amount, is capable of inducing cellular immunity against the native HIV protein to which the active peptide of the multimer corresponds in sequence, but is not capable of inducing production of antibodies that immunoreact with that native HIV protein.

    摘要翻译： 公开了主要由7至约30个宿主组成的并且具有对应于HIV蛋白质的保守结构域的序列的活性肽，以及含有该多肽的多聚体，含有多聚体的含水组合物以及使用和制备该多聚体的方法 。 含有免疫有效量的活性肽多聚体的含水组合物当以免疫有效量引入免疫活性宿主动物时能够诱导针对多聚体的活性肽依次对应的天然HIV蛋白的细胞免疫， 但不能诱导产生与该天然HIV蛋白免疫反应的抗体。

    HIV-specific T-cell induction
    9.
    发明授权
    HIV-specific T-cell induction 失效
    HIV特异性T细胞诱导

    公开(公告)号：US07306804B2

    公开(公告)日：2007-12-11

    申请号：US10673671

    申请日：2003-09-29

    申请人： K. Jagannadha Sastry ,  Ralph B. Arlinghaus ,  Pramod N. Nehete

    发明人： K. Jagannadha Sastry ,  Ralph B. Arlinghaus ,  Pramod N. Nehete

    IPC分类号： A61K38/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2740/16122 ,  G01N33/5091 ,  G01N33/56977 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  Y10S530/826

    摘要： This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.

    摘要翻译： 本发明公开了AIDS的诊断，预防和治疗方法，涉及确定受试者是否表现HLA-Cw7限制性CTL应答。 一些方法涉及使用HLA-Cw7作为长期非进展和治疗疗法适应性的遗传标记。 诊断方法包括预测HIV感染受试者长期不进展的方法。 预防和治疗方法包括确定受试者是否表现出HLA-Cw7限制性CTL应答。 如果有必要，它们还包括引发此类响应的方法。 此外，一些方法包括施用一种或多种HIV多肽或肽或编码它们的多核苷酸作为预防AIDS发展的治疗疗法。